Create a Report

Please provide report title
Please provide location
Please provide details

Get alerts and updates for your case!

This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.

Please provide email or phone
Please provide email or phone

We do not show your email or contact info

Skip this step

Add photos or video

We recommend photos and videos to help explain your report

Add Photo/Video
Skip this step

Email or SMS copy of report

Enter below to get emailed a copy of your report, or sms a link to your report

Please provide email or phone
Please provide email or phone

Thank you for your report!


IMPORTANT - Your report is queued
It may take up to 12 hours to process your report.


Email us at support@safelyhq.com if you have questions.

Report by

Safety Report: Zendedi dextroamphetamine sulfate tablets - recalled due to mislabeled package, USA

4 months ago source fda.gov

Recall notice

United States

Azurity Pharmaceuticals, Inc. is voluntarily recalling one lot (F230169A) of Zenzedi® CII (dextroamphetamine sulfate tablets, USP) 30 mg to the consumer level. The product is being recalled due to a report from a pharmacist in Nebraska who opened a bottle of Zenzedi® 30 mg tablets and found tablets of Carbinoxamine Maleate, an antihistamine drug. The product was distributed nationwide through pharmacies. To date, Azurity has not received any reports of serious adverse events related to this recall.

Patients who take carbinoxamine instead of Zenzedi® will experience undertreatment of their symptoms, which may result in functional impairment and an increased risk of accidents or injury. Patients who unknowingly consume carbinoxamine could experience adverse events which include, but are not limited to, drowsiness, sleepiness, central nervous system (CNS) depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder. For patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy (sleep disorder) there is a reasonable probability that accidents or injuries that occur due to the sedating effects of carbinoxamine, could lead to ongoing disability or death in severe cases, particularly if individuals who use it (unaware that they have not received Zenzedi®) engage in activities requiring significant focus and alertness (e.g., driving, operating heavy machinery).

Zenzedi® is a prescription medicine for the treatment of Narcolepsy. Zenzedi® is also indicated as a treatment for attention deficit hyperactivity disorder (ADHD). Zenzedi® is marketed under Arbor Pharmaceuticals, LLC brand. Arbor Pharmaceuticals, LLC is a subsidiary of Azurity Pharmaceuticals, Inc.

Zenzedi® 30 mg tablets can be identified by light yellow hexagonal tablet debossed with “30” on one side and “MIA” on the other side and distributed in a white bottle with black writing and “30 mg” highlighted yellow. Whereas the description of the suspect tablets (Carbinoxamine Maleate Tablets USP, 4 mg), which was provided by the reporting pharmacist, was white round tablets with imprints of “GL” on one side and “211” on the other side. Following are the details of the recalled product:

- Product: Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg, NDC No.: 24338-856-03, Lot No.: F230169A, Exp. Date: 2025-06, Ship Dates to Wholesalers: 08/23/2023 – 11/29/2023.

Azurity Pharmaceuticals, Inc. sent recall notification letters via overnight delivery to wholesale distributors on January 4, 2024, and arranged for the return of all recalled products at that wholesaler level. Consumers who have a product that is being recalled should stop using and return to place of purchase. Azurity is working with wholesalers and retailers to arrange for the return and replacement of recalled product.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

In case you experience harm from this product, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance. If symptoms persist, seek medical care.

Company name: Azurity Pharmaceuticals, Inc.
Brand name: Zendedi
Product recalled: dextroamphetamine sulfate tablets, 30 mg
Reason of the recall: Mislabeled package
FDA Recall date: January 25, 2024

Source: www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/azurity-pharmaceuticals-inc-issues-voluntary-nationwide-recall-zenzedir-dextroamphetamine-sulfate

#drugs #recall #us

Recent Interesting Reports

Mars Petcare US is voluntarily recalling 315 bags of PEDIGREE® Adult Complete Nutrition Grilled Steak & Vegetable Flavor Dry Dog Food in the 44 lb. bag size only, due to the potential presence of loose metal pieces in the bag. The product was sold by Walmart in… See more

#dogfood #petfood #dallas #texas #us

W
I received a bottle of Keto+ACV gummies in the mail but do not know why. First, I did not order this gummies, second, I am worried that whoever accessed my card might keep charging me. There is no phone # in the bottle just address. There is… See more

#unorderedpackage #ketogummiesscam #delivery #newyork #us

J
I mailed a package to TX, PO at Beechnut delivered my package to a different location than addressed. I had insurance on it because of the price of items in the package. The POIns wanted a value I sent the credit card statement with the price of… See more

#uspostalservice #houston #texas #us

Last 30 days